Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis Sells 500 Shares

Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Edwards Lifesciences Trading Down 0.1 %

Shares of EW stock opened at $69.77 on Friday. The stock has a market cap of $41.15 billion, a P/E ratio of 10.07, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a 50 day simple moving average of $72.06 and a 200 day simple moving average of $71.45.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.59 EPS. On average, research analysts predict that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Edwards Lifesciences

Large investors have recently modified their holdings of the business. Oppenheimer Asset Management Inc. grew its position in Edwards Lifesciences by 2.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 21,983 shares of the medical research company’s stock valued at $2,031,000 after acquiring an additional 615 shares during the last quarter. J.W. Cole Advisors Inc. boosted its stake in shares of Edwards Lifesciences by 7.4% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 2,956 shares of the medical research company’s stock valued at $273,000 after purchasing an additional 204 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Edwards Lifesciences by 18.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,399,329 shares of the medical research company’s stock valued at $129,271,000 after purchasing an additional 219,486 shares during the last quarter. Edgestream Partners L.P. acquired a new position in Edwards Lifesciences during the 2nd quarter worth approximately $438,000. Finally, Bradley Foster & Sargent Inc. CT lifted its stake in Edwards Lifesciences by 17.9% in the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 16,842 shares of the medical research company’s stock valued at $1,556,000 after purchasing an additional 2,563 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $82.00 to $90.00 in a report on Monday, December 16th. Citigroup lifted their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $78.48.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.